EirGenix Inc. (TPE:6589)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
61.20
+0.20 (0.33%)
At close: Feb 11, 2026
Market Cap18.52B -24.2%
Revenue (ttm)936.18M -20.0%
Net Income-705.76M
EPS-2.33
Shares Out302.60M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume400,172
Average Volume594,505
Open61.00
Previous Close61.00
Day's Range59.60 - 61.60
52-Week Range52.70 - 84.30
Beta0.57
RSI42.61
Earnings DateMar 18, 2026

About EirGenix

EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally. The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services. It is also involved in the development of EG12014/EGI014, a Trastuzumab biosimilar, indicated for the treatment of cancer and currently under biologics license application status; EG1206A, a Pertuzumab biosimilar, indicated for the treatment of cancer and curr... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 1,000
Stock Exchange Taiwan Stock Exchange
Ticker Symbol 6589
Full Company Profile

Financial Performance

In 2024, EirGenix's revenue was 1.01 billion, a decrease of -1.34% compared to the previous year's 1.02 billion. Losses were -698.34 million, -23.70% less than in 2023.

Financial Statements